Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease

Emerging SARS-CoV-2 variants continue to threaten the effectiveness of COVID-19 vaccines, and small-molecule antivirals can provide an important therapeutic treatment option. The viral main protease (M(pro)) is critical for virus replication and thus is considered an attractive drug target. We perfo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kneller, Daniel W., Li, Hui, Phillips, Gwyndalyn, Weiss, Kevin L., Zhang, Qiu, Arnould, Mark A., Jonsson, Colleen B., Surendranathan, Surekha, Parvathareddy, Jyothi, Blakeley, Matthew P., Coates, Leighton, Louis, John M., Bonnesen, Peter V., Kovalevsky, Andrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046211/
https://www.ncbi.nlm.nih.gov/pubmed/35477935
http://dx.doi.org/10.1038/s41467-022-29915-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046211/
https://www.ncbi.nlm.nih.gov/pubmed/35477935
http://dx.doi.org/10.1038/s41467-022-29915-z

Ejemplares similares